托弗森:一种用于治疗肌缩侧面硬化症的新选择
Michael Karros1, Marissa DiFulco1, Anna Nogid1
1Fairleigh Dickinson University College of Pharmacy and Health Sciences, Florham Park, NJ, USA.
The Annals of pharmacotherapy
|February 5, 2026
概括
托弗森 (Qalsody) 是一种用于治疗SOD1-胺转移性侧面硬化症 (ALS) 的基因导向疗法. 它降低了SOD1蛋白,并减缓了疾病的进展,为这种ALS遗传形式提供了向治疗.
科学领域:
- 神经学 神经学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 肌缩侧面硬化症 (ALS) 是一种进展性神经退行性疾病.
- 超氧化解突变酶1 (SOD1) 基因的突变是家族性ALS的已知原因之一.
- 需要有针对性的疗法来解决ALS的潜在遗传机制.
研究的目的:
- 审查托弗森 (卡尔索迪) 治疗SOD1-ALS的疗效和安全性.
- 评估托弗森在临床实践中作为基因导向疗法的作用.
- 将tofersen的结果与现有的ALS治疗方法进行比较.
主要方法:
- 在PubMed,MEDLINE,Google Scholar和clinicalTrials.gov.gov的综合文献搜索中进行了全面的文献搜索.
- 包括对托弗森的药理动力学,药理学,疗效和安全性的英语研究.
- 对托弗森的处方信息和现实世界的证据的审查.
主要成果:
- 托弗森是一种反感性寡核酸,可降低SOD1的mRNA和蛋白质水平.
- 早期的研究表明,CSF SOD1的剂量依赖性降低和ALSFRS-R下降速度较慢.
- 第三阶段试验表明,CSF SOD1和血NfL减少,但与安慰剂相比,ALSFRS-R没有显著差异.
- 现实世界的数据表明,患者的治疗结果和ALSFRS-R的改善是有利的.
- 副作用主要与腰部穿刺有关;7%的人经历了严重的神经事件.
结论:
- 托弗森是FDA批准的SOD1ALS的第一个基因导向疗法,针对遗传原因.
- 对于具有致病性SOD1突变的个体来说,它是一个有前途的治疗选择.
- 需要进一步的研究,以充分阐明其长期临床影响,并优化其使用.
相关概念视频
Lateralization
1.1K
Brain lateralization refers to the division of mental processes and functions between the two hemispheres of the brain, a phenomenon that optimizes neural efficiency and underpins complex abilities in humans. This specialization allows each hemisphere to perform tasks where it has a comparative advantage, facilitating more refined cognitive capabilities across different domains.
1.1K
Cranial Bones: Lateral View
4.5K
The lateral view of the cranium is dominated by temporal, sphenoid, and ethmoid bones.
The temporal bone forms the lower lateral side of the skull. The temporal bone is subdivided into several regions. The flattened upper portion is the squamous portion of the temporal bone. Below this area and projecting anteriorly is the zygomatic process of the temporal bone, which forms the posterior portion of the zygomatic arch. Posteriorly is the mastoid portion of the temporal bone. Projecting...
The temporal bone forms the lower lateral side of the skull. The temporal bone is subdivided into several regions. The flattened upper portion is the squamous portion of the temporal bone. Below this area and projecting anteriorly is the zygomatic process of the temporal bone, which forms the posterior portion of the zygomatic arch. Posteriorly is the mastoid portion of the temporal bone. Projecting...
4.5K
Open Angle Glaucoma: Treatment
1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment
959
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
959


